2014 ACR/ARHP Annual Meeting

November 14-19, 2014. Boston, MA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2927

Baseline Serum Interferon Beta/Alpha Ratio Predicts Response to Tumor Necrosis Factor Alpha Inhibition in Rheumatoid Arthritis
Abstract Number: 2839

BCL-2 As a Potential Therapeutic Target in Human Lupus Tubulointerstitial Inflammation
Abstract Number: 1212

Behcets Disease in Females Due to Mutation in NEMO, the NF-Kb Essential Modulator
Abstract Number: 671

Belimumab Reduces the Frequency of Flares in Patients with Refractory SLE: DATA from Clinical Practice Setting
Abstract Number: 7

Beneficial Effects of in Vivo Ubiquinol Supplementation on Athero-Thrombosis Prevention in Antiphospholipid Syndrome Patients
Abstract Number: 2103

Benefits of Early Onset of DAS28 (CRP) <2.6 on Physical Functioning, Quality of Life and Resource Use Among RA Patients in a Clinical Practice Setting
Abstract Number: 2313

Best Practices for Best Practice Alerts: Evaluation of a Best Practice Alert to Detect Chronic Glucocorticoid Use
Abstract Number: 2815

Better Functional Ability with Less Biologicals 2 years after Induction with Combination DMARD Therapy versus methotrexate Monotherapy
Abstract Number: 569

Better Outcomes in Ankylosing Spondylitis: The Synergistic Association Between Exercise and Tumor Necrosis Factor Inhibitors
Abstract Number: 1545

Better Performance of the Leeds and Sparcc Enthesitis Indices Compared to the Mases in Patients with Peripheral Spondyloarthritis during Treatment with Adalimumab
Abstract Number: 425

Beyond Disease Activity: Patient Global Scores Also Reflect Treatment Expectations and Emotional Reactions to Living with Rheumatoid Arthritis
Abstract Number: 2166

Bim Suppresses the Development of Glomerulonephritis By Inhibiting M2 Polarization
Abstract Number: 501

Bio-naïve Patients with Rheumatoid Arthritis Benefit More from Abatacept Treatment Compared to Those Who Are Inadequate Responders to Other Biologics – Results from the National Swedish Rheumatology Quality Register
Abstract Number: 1049

Bioactive TGF-β Is Present on Bovine Milk-Derived Exosomes: Consequences for Patients?
Abstract Number: 941

Biologic De-Escalation in Rheumatoid Arthritis: Cost Savings and Clinical Success

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].